301080
vs
S
Shanghai Composite
301080
Over the past 12 months, Acrobiosystems Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +83% compared to the Shanghai Composite's +30% growth.
Stocks Performance
301080 vs Shanghai Composite
Performance Gap
301080 vs Shanghai Composite
Performance By Year
301080 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Acrobiosystems Co Ltd
Glance View
ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.